Integral Health Asset Management LLC Takes Position in Insulet Co. (NASDAQ:PODD)

Integral Health Asset Management LLC purchased a new stake in shares of Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 20,000 shares of the medical instruments supplier’s stock, valued at approximately $5,221,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PODD. SBI Securities Co. Ltd. bought a new position in Insulet in the fourth quarter valued at about $36,000. Itau Unibanco Holding S.A. bought a new position in Insulet in the fourth quarter valued at about $42,000. SRS Capital Advisors Inc. increased its position in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial purchased a new stake in Insulet in the fourth quarter worth about $57,000. Finally, Assetmark Inc. increased its position in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock worth $69,000 after buying an additional 246 shares in the last quarter.

Insider Buying and Selling

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now owns 3,231 shares of the company’s stock, valued at approximately $888,525. The trade was a 36.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.47% of the company’s stock.

Insulet Stock Up 20.8%

NASDAQ:PODD opened at $310.42 on Monday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock’s fifty day moving average is $257.45 and its two-hundred day moving average is $263.88. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $312.80. The stock has a market capitalization of $21.84 billion, a price-to-earnings ratio of 53.61, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million for the quarter, compared to analysts’ expectations of $543.20 million. During the same period last year, the firm earned $0.73 earnings per share. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. Research analysts anticipate that Insulet Co. will post 3.92 EPS for the current year.

Analysts Set New Price Targets

PODD has been the subject of a number of analyst reports. Oppenheimer upped their price target on Insulet from $312.00 to $324.00 and gave the stock an “outperform” rating in a research report on Friday. Piper Sandler increased their target price on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Royal Bank of Canada initiated coverage on Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price on the stock. Raymond James reissued an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $303.81.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.